Literature DB >> 20833272

The meaning of anti-Ro and anti-La antibodies in primary Sjögren's syndrome.

Gabriela Hernández-Molina1, Gustavo Leal-Alegre, Martha Michel-Peregrina.   

Abstract

Anti-SSA/Ro and anti-La/SSB are the hallmark antibodies in primary Sjögren's syndrome (pSS), being present in 60-70%. These antibodies have been associated with an earlier disease onset, glandular dysfunction and extraglandular manifestations as well as with other B cells activation markers. In addition an immunogenetic background is important for the autoantibody formation, having a stronger association with HLA-DR2 and HLA-DR3. Anti-Ro/SSA and anti-La/SSB antibodies are useful in the diagnosis of pSS and help to identify more "active" patients, however their association with response to treatment is unclear. Herein we review the evidence regarding the association of these antibodies with HLA background, demographic, clinical, glandular dysfunction, other serologic features and response to treatment in patients with pSS. Copyright Â
© 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20833272     DOI: 10.1016/j.autrev.2010.09.001

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  35 in total

1.  Upregulation of long noncoding RNA TMEVPG1 enhances T helper type 1 cell response in patients with Sjögren syndrome.

Authors:  Juan Wang; Huiyong Peng; Jie Tian; Jie Ma; Xinyi Tang; Ke Rui; Xinyu Tian; Yungang Wang; Jianguo Chen; Liwei Lu; Huaxi Xu; Shengjun Wang
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

2.  [Manifestations of autoimmune disorders in otorhinolaryngology : Classical symptoms and diagnostic approach].

Authors:  B Hofauer; A Chaker; K Thürmel; A Knopf
Journal:  HNO       Date:  2017-08       Impact factor: 1.284

Review 3.  Prenatal evaluation and management of fetuses exposed to Anti-SSA/Ro antibodies.

Authors:  Anita Krishnan; Jodi I Pike; Mary T Donofrio
Journal:  Pediatr Cardiol       Date:  2012-05-22       Impact factor: 1.655

Review 4.  The autoimmune side of heart and lung diseases.

Authors:  Nancy Agmon-Levin; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

Review 5.  Autoimmunity in 2011.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2012-08       Impact factor: 8.667

6.  Survey of Ophthalmologists Regarding Practice Patterns for Dry Eye and Sjogren Syndrome.

Authors:  Vatinee Y Bunya; Karen B Fernandez; Gui-Shuang Ying; Mina Massaro-Giordano; Ilaria Macchi; Michael E Sulewski; Kristin M Hammersmith; Parveen K Nagra; Christopher J Rapuano; Stephen E Orlin
Journal:  Eye Contact Lens       Date:  2018-11       Impact factor: 2.018

7.  Autoimmune manifestations in aged mice arise from early-life immune dysregulation.

Authors:  Tamer I Mahmoud; Jingya Wang; Jodi L Karnell; Qiming Wang; Shu Wang; Brian Naiman; Phillip Gross; Philip Z Brohawn; Chris Morehouse; Jordan Aoyama; Clive Wasserfall; Laura Carter; Mark A Atkinson; David V Serreze; Helen Braley-Mullen; Tomas Mustelin; Roland Kolbeck; Ronald Herbst; Rachel Ettinger
Journal:  Sci Transl Med       Date:  2016-10-19       Impact factor: 17.956

8.  Primary Sjögren's syndrome related optic neuritis.

Authors:  Wei-Qiang Tang; Shi-Hui Wei
Journal:  Int J Ophthalmol       Date:  2013-12-18       Impact factor: 1.779

9.  Serologic features of primary Sjögren's syndrome: clinical and prognostic correlation.

Authors:  Mario García-Carrasco; Claudia Mendoza-Pinto; César Jiménez-Hernández; Mario Jiménez-Hernández; Arnulfo Nava-Zavala; Carlos Riebeling
Journal:  Int J Clin Rheumtol       Date:  2012-12

10.  PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjögren's syndrome.

Authors:  David F Fiorentino; Matthew Presby; Alan N Baer; Michelle Petri; Kerri E Rieger; Mark Soloski; Antony Rosen; Andrew L Mammen; Lisa Christopher-Stine; Livia Casciola-Rosen
Journal:  Ann Rheum Dis       Date:  2015-08-07       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.